CDMO Neuland Laboratories said its new commercial peptide production facility at Bonthapally, India, will open its first module this summer, adding multi‑kiloliter SPPS and LPPS capacity to service growing peptide demand, including GLP‑1 programs. Module one already has roughly $30 million in committed business, and Neuland plans further modular expansions to reach multi‑ton volumes. The site complements Neuland’s large API footprint and R&D center, and the company expects to more than double manufacturing headcount to support commercialization. Management pitched the facility as a strategic response to tightening peptide capacity globally and as a platform to capture innovator and emerging biotech programs requiring scale and complex long‑chain synthesis. The expansion underscores continued demand for peptide therapeutics and the manufacturing investments CDMOs are making to relieve development bottlenecks.